Search Results - wenqing+li

3 Results

Sort By:

Bioplatform to Identify and Characterize Pathogens and Therapies against Tuberculosis and Other Granulomatous Diseases.

Treatment for human tuberculosis (TB) and other granulomatous diseases would benefit from high- throughput screening (HTS)-compatible platform replicating physiological conditions in hallmark granuloma lesions. However, currently available screening platforms and 2-D and 3-D cell culture systems lack throughput and key features, and relevant microenvironments...

Published: 5/9/2025 | Inventor(s): Suraj Sable, James Posey, Wen Li, Allison Kline

Keywords(s):

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics

Abstract: Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network...

Published: 4/22/2025 | Inventor(s): Joel Schneider, Stephen Miller, Yuji Yamada, Steven Tau, Julie Hixon, Wenqing Li, Caroline Andrews, Scott Walsh

Keywords(s): DEVICE, IL-7, Nanoparticle, Peptide, Peptide-based Hydrogel, Protein, Schneider, small molecule, T Cell Enhancer, Whole Cell Delivery System

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Immunology

IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)

Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment. The...

Published: 4/23/2025 | Inventor(s): Scott Durum, Julie Hixon, Wenqing Li, Scotch Walsh, Lila Kashi

Keywords(s): Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration